Graphical abstract
SUCLA2 gene is frequently involved in the deletion of RB1 gene region, which occurs in 10 – 30 % of advanced prostate cancers. SUCLA2 deletion gives rise to a metabolic vulnerability. By screening chemical compounds, thymoquinone appeared to selectively kill SUCLA2-deficeint prostate cancer cells.
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patients.
Hormone therapy is often chosen for the treatment of metastatic prostate cancer but nearly half of patients develop resistance to the treatment in as little as 2 years. A mutation in RB1, a tumor suppressor gene that keeps cell growth under control, has been pegged as a particularly strong driver of treatment resistance and predicts poor outcome in patients.
“Mutations in tumor suppressor genes are enough to induce initiation and malignant progression of prostate cancer, but so far we haven’t been able to directly target these mutations with drugs to treat prostate cancer,” says the lead author Susumu Kohno. “We wanted to find a genetic aberration associated with that of a tumor suppressor gene which we could target therapeutically.”
In the genome, SUCLA2 neighbors RB1. An analysis of prostate cancer cells showed that cells with a RB1 deletion were also missing SUCLA2, pairing up the SUCLA2 deletion with the RB1 deletion present in advanced stage prostate cancer. Kohno and colleagues analyzed prostate cancer tissue and found that 11% of cases were missing both SUCLA2 and RB1.
The researchers screened compounds to identify drugs that would selectively kill cells with a SUCLA2 deletion. Out of around 2,000 compounds, TQ emerged as a hit compound. TQ already has known anti-cancer effects and was shown to be safe in a phase I clinical trial. Kohno and colleagues applied the TQ treatment to a mouse model of SUCLA2-deficient prostate cancer and TQ selectively suppressed tumor growth.
“These findings show that TQ treatment could be an effective therapy for treating prostate cancer cells that harbor SUCLA2 deficiency” says the senior author Chiaki Takahashi.
In a search of genetic databases from patients with prostate cancer, the researchers found that the frequency of SUCLA2 loss was almost perfectly aligned with RB1 loss at every disease stage—meaning the SUCLA2 deletion could identify people with prostate cancer needing advanced therapy.
Finding this drug-targetable vulnerability opens a crack in the barrier of treatment resistance for prostate cancer. More work needs to be done to improve efficacy of TQ and identify patients that would benefit from this type of treatment, but the compound provides a promising route for new treatment options for advanced prostate cancer.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Advanced prostate cancer
- AUA 2024: Anticipating Developments in Metastatic Prostate Cancer Research
AUA 2024 offers valuable learning opportunities, including forums on advanced prostate cancer and instructional courses on the new AUA guidelines. In addition, new programs like P2s and Clinical ...
- Moving Treatments Earlier in Prostate Cancer Can Prevent Progression, Additional Treatment
New therapies being developed are moving into earlier lines of therapy, with the idea that most patients with early-stage prostate cancer will progress and need additional therapy later.
- Radiotherapy with hormone therapy can help some advanced prostate cancer patients avoid chemotherapy
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, ...
- New trial finds radiotherapy combined with hormone therapy can help some advanced prostate cancer patients avoid chemotherapy
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, ...
- Prostate cancer hope as patients could get painless treatment instead of chemo
Currently patients with a form of the disease which has spread to one or two other parts of the body are assumed to be resistant to milder hormone therapy drugs ...
Go deeper with Google Headlines on:
Advanced prostate cancer
[google_news title=”” keyword=”advanced prostate cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Prostate cancer
- SA upper house MP Frank Pangallo reveals stage 4 prostate cancer diagnosis
The independent MP says he is sharing his cancer diagnosis publicly to raise awareness, and says he plans to continue to fulfil his obligations to the state while he receives treatment.
- Independent MLC Frank Pangallo talks about his stage four prostate cancer diagnosis
Mr Pangallo said, while there was still a way to go before he received the all-clear from his doctors, he decided to share his cancer battle to encourage all men, no matter their age, to get checked. ...
- Turning Over a New Leaf: Plant-Based Diets Help Alleviate Prostate Cancer Symptoms
The research investigating the impact of a plant-based diet on the symptoms of prostate cancer was published in the Cancer Journal.Read more: Study Links Food Additives to Increased Risk of Type 2 ...
- “Here’s How I Knew I Had Prostate Cancer”: One Patient’s Story of Abruptly Elevated Markers
The prostate is a small gland located in the male reproductive system that's essential for producing seminal fluid. When it's healthy, the prostate is shaped similarly to a walnut, but prostate cancer ...
- AUA 2024: Anticipating Developments in Metastatic Prostate Cancer Research
AUA 2024 offers valuable learning opportunities, including forums on advanced prostate cancer and instructional courses on the new AUA guidelines. In addition, new programs like P2s and Clinical ...
Go deeper with Google Headlines on:
Prostate cancer
[google_news title=”” keyword=”prostate cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]